Sparsentan

COMPOSITION:

Each film-coated tablet contains: Sparsentan…………………………….… 400mg.

Each film-coated tablet contains: Sparsentan…………………………….… 200mg.

INDICATION:

LuciSeta is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

DOSAGE AND USE:

· Prior to initiating treatment with LuciSeta, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists (ERAs) or aliskiren.

· Initiate treatment with LuciSeta at 200 mg orally once daily. After 14 days, increase to the recommended dose of 400 mg once daily, as tolerated. When resuming treatment with LuciSeta after an interruption, consider titration of LuciSeta, starting at 200 mg once daily. After 14 days, increase to the recommended dose of 400 mg once daily.

Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos.

WARNING:

Keep medicine out of reach of Children.

Do not administered LuciSeta in Pregnancy and Lactation patient treatment.